The Japan Drug Delivery Devices Market is expected to register a CAGR of nearly 4.5% during the forecast period. The major factors driving the Japan Drug Delivery Devices Market are the rising prevalence of chronic diseases and technological advancements.
Drug delivery devices help in delivering the drugs which are beneficial for the targeted population to recover faster. In addition, a rising number of cancers, respiratory are diabetic patients in Japan will promote the adoption of drug delivery devices and drive the overall market. For instance, according to the estimates of the National Cancer Center - Center for Cancer Control and Information Services, the cancer incidence in 2018 was 1,013,600 in Japan, while the most common types of cancer were colorectum, stomach, lung, breast, and prostate cancer. Thus, owing to the above-mentioned factors is expected to drive market growth over the forecast period.
Key Market Trends
By Application Cancer is Estimated to Witness a Healthy Growth Over The Forecast Period
Over the years, cancer incidence and mortality have increased in Japan. For instance, according to the World Health Organization (WHO), 2018 statistics indicate that the deaths due to cancer increased to nearly 409,400, in Japan. The increasing mortality rate has been a concerning factor for the Japanese government over the years. As a result, the government and other organizations are taking initiatives to spread awareness regarding cancer and its treatments which is expected to boost the market. Thus, the rising prevalence of cancer and the presence of better R&D infrastructure in the country is expected to drive market growth in the near future.
Competitive Landscape
The Japan Drug Delivery Devices Market is fragmented competitive and consists of several major players. Some of the companies which are currently dominating the market are Mylan N.V., ANTARES PHARMA, INC., Tasei Kako Co. Ltd., GlaxoSmithKline Plc, Novartis AG, Bayer AG, Becton, Dickinson and Company, Johnson & Johnson and 3M Company.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
Methodology
LOADING...
